Companies: 10,795·Total market cap: $144.5T
Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.

RARENASDAQHealthcare● Active
$21.59
$-0.32(-1.46%)
Market Cap$2.1B
P/E Ratio
52W High$42.37
52W Low$18.29
Overview

Ultragenyx Pharmaceutical Inc. (RARE) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · RARE · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-6.11rare eps ttm · rare earnings per shareEarnings history
PE Ratio (TTM)rare pe ratio ttm · rare price to earningsPE Ratio deep dive
Revenue (TTM)$669.4Mrare revenue ttm · rare annual revenueFull revenue history
Dividend YieldNo Dividenddoes rare pay dividends · rare dividend yieldDividend history
Shares Outstanding98.6Mrare shares outstanding · rare floatShares outstanding history
Next EarningsAug 4, 2026Est.rare earnings date · rare next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$673.0M▲ +20.13% YoY
202320242025
ultragenyx pharmaceutical inc. revenue · rare revenue 2025
FY 2025Net Income-$575.0M▼ 1.02% YoY
202320242025
ultragenyx pharmaceutical inc. net income · rare profit 2025
FY 2025EPS$-5.83▲ +7.31% YoY
202320242025
rare eps · ultragenyx pharmaceutical inc. earnings per share 2025
TTM:Revenue: $669.4MNet Income: -$609.4MEPS: $-6.11View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy33 analystsis rare a buy · rare analyst rating
Strong Buy
0
Buy
27
Hold
5
Sell
1
Strong Sell
0
12-Month Price Target
$26.00Low
$21.59Current
$48.36Avg Target123.99% upside
$67.00High
rare price target · rare 12 month forecast

Total: 33 · Buy rate: 81.8%

The RARE analyst consensus is Buy, based on ratings from 33 Wall Street analysts over the past 3 months. The average 12-month price target is $48.36, representing +123.99% upside from the current price of $21.59.

Stock Performance

Full History
1D-1.46%
1W-1.19%
1M-17.34%
3M+1.60%
YTD-6.13%
1Y-41.71%
5Y-76.90%

About Ultragenyx Pharmaceutical Inc.

CEOEmil D. Kakkis
IPO DateJan 31, 2014
Employees1,294
CountryUS

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations sp…

what is ultragenyx pharmaceutical inc. · rare stock overview · ultragenyx pharmaceutical inc. company profile · who is ultragenyx pharmaceutical inc. ceo · rare NASDAQ · ultragenyx pharmaceutical inc. headquarters · ultragenyx pharmaceutical inc. business segments

About Stock Overview & Key Data

Ultragenyx Pharmaceutical Inc. (RARE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 31, 2014. As of the latest trading session, RARE stock price is $21.59, with a market capitalization of $2.1B. The stock has returned -41.71% over the past 12 months and -6.13% year-to-date.

According to 33 Wall Street analysts, the consensus rating for Ultragenyx Pharmaceutical Inc. stock is Buy, with an average 12-month price target of $48.36. In fiscal year 2025, Ultragenyx Pharmaceutical Inc. reported revenue of $673.0M and net income of -$575.0M. For detailed data — including Ultragenyx Pharmaceutical Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Ultragenyx Pharmaceutical Inc. (RARE) stock price is $21.59. The stock is traded on NASDAQ under the ticker symbol RARE. The 52-week range is $18.29 – $42.37.

RARE stock priceRARE quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice